TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07327619: A Multicenter, Randomized, Double-blind, Active-Controlled, Parallel, Phase Ⅲ Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam for Injection Compared to Ceftazidime and Avibactam Sodium for Injecti

Sponsor: Qilu Pharmaceutical Co., Ltd. · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 420 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$13,359,360

Rescue Site Savings

+$8,808,828

Unlock Full NCT07327619 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07327619 Rescue Dossier →